Avacta Therapeutics

Avacta is clinical stage biotech company developing novel cancer immunotherapies combining its two proprietary platforms – pre|CISION™ tumour targeted chemotherapy and novel biological entity (NBE) Affimer biotherapeutics. 
Avacta is in Phase 1 clinical development with its pathfinder pre|CISION programme AVA6000, a Fibroblast Activation Protein (FAP) activated chemotherapy. The Affimer programmes include Affimer PD-L1 bispecifics and immune cytokine fusions as well as combinations with pre|CISION to create novel tumour microenvironment activated drug conjugates (TMAC).